Diabetes technologies such as continuous glucose monitoring (CGM), continuous subcutaneous insulin infusions (‘insulin pumps’) and hybrid closed-loop (HCL) therapies have been shown to improve glycaemia and patient-reported outcomes in T1DM, with increasing evidence also suggesting benefits of these in type 2 diabetes (T2DM)3, 4, 5 . The gene discussed is INS; the disease is type 1 diabetes mellitus.